1. Home
  2. CBU vs NAMS Comparison

CBU vs NAMS Comparison

Compare CBU & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Community Bank System Inc.

CBU

Community Bank System Inc.

HOLD

Current Price

$66.82

Market Cap

3.6B

Sector

Finance

ML Signal

HOLD

Logo NewAmsterdam Pharma Company N.V.

NAMS

NewAmsterdam Pharma Company N.V.

HOLD

Current Price

$35.15

Market Cap

4.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CBU
NAMS
Founded
1866
2019
Country
United States
Netherlands
Employees
N/A
100
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.6B
4.1B
IPO Year
1994
N/A

Fundamental Metrics

Financial Performance
Metric
CBU
NAMS
Price
$66.82
$35.15
Analyst Decision
Hold
Strong Buy
Analyst Count
4
8
Target Price
$66.67
$46.75
AVG Volume (30 Days)
394.6K
1.1M
Earning Date
04-29-2026
05-06-2026
Dividend Yield
3.02%
N/A
EPS Growth
15.41
N/A
EPS
1.08
N/A
Revenue
$818,007,000.00
N/A
Revenue This Year
$13.46
$17.96
Revenue Next Year
$7.75
$540.65
P/E Ratio
$61.38
N/A
Revenue Growth
9.61
N/A
52 Week Low
$51.12
$20.53
52 Week High
$69.23
$42.21

Technical Indicators

Market Signals
Indicator
CBU
NAMS
Relative Strength Index (RSI) 55.78 57.67
Support Level $60.90 $33.83
Resistance Level $66.99 $37.27
Average True Range (ATR) 1.45 1.74
MACD -0.07 0.42
Stochastic Oscillator 67.75 71.06

Price Performance

Historical Comparison
CBU
NAMS

About CBU Community Bank System Inc.

Community Financial System Inc is a diversified financial services company providing a broad array of banking and other financial services to retail, commercial, institutional, and governmental customers. The Company also offers comprehensive financial planning, trust administration, and wealth management services through its Community Bank Wealth Management operating unit. It has four reportable operating business segments: Banking and Corporate, Employee Benefit Services, Insurance Services, and Wealth Management Services. The group generates the majority of its revenue from the Banking and Corporate segment.

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.

Share on Social Networks: